![Wioleta Zelek](https://profiles-cardiff.imgix.net/attachments/2652?w=200&h=200&auto=format&crop=faces&fit=crop&q=90")
Wioleta Zelek
(hi/ei)
- Ar gael fel goruchwyliwr ôl-raddedig
Timau a rolau for Wioleta Zelek
Arweinydd Grŵp, Sefydliad Ymchwil Dementia y DU
Trosolwyg
Rwy'n Arweinydd Grŵp yn Sefydliad Ymchwil Dementia y DU ym Mhrifysgol Caerdydd ac yn Gymrawd Arweinwyr y Dyfodol UKRI. Mae fy ymchwil yn canolbwyntio ar ddeall sut mae'r system complement yn rheoleiddio iechyd yr ymennydd ac yn cyfrannu at glefyd niwroddirywiol.
Mae gen i ffocws ymchwil cryf ar y system ategu, ei bioleg, a'i rolau mewn clefydau, yn ogystal â strategaethau i drin y system ar gyfer therapi. Mae fy ngwaith yn cynnwys datblygu blwch offer o atalyddion cyflenwi, gan gynnwys gwrthgyrff a moleciwlau bach, sy'n targedu gwahanol lwybrau cyflenwad ac sy'n croes-adweithiol â phobl a chnofilod. Er mwyn mesur dysregulation cyflenwad yn fanwl, rwyf wedi datblygu profion a gwrthgyrff sy'n galluogi canfod a meintioli cywir, gan gefnogi darganfod biofarcwyr ac ymchwil drosiannol.
Mae fy nhîm yn cyfuno astudiaethau dynol, modelau arbrofol, darganfod biofarcwyr, a datblygiad therapiwtig i nodi triniaethau newydd ar gyfer clefyd Alzheimer a chlefydau llidiol eraill yr ymennydd. Un o brif ffocws fy rhaglen yw datblygu therapiwteg cyflenwad sy'n amddiffyn synapsau, lleihau niwrolid, ac arafu dilyniant clefyd.
https://www.raceagainstdementia.com/rad-fellows/dr-wioleta-zelek/
Cyhoeddiad
2026
- Arun, T. et al., 2026. Non-invasive biomarkers for neurosarcoidosis: Complement activation as a tool for diagnosis and prognosis. Journal of Neuroimmunology 418 578969. (10.1016/j.jneuroim.2026.578969)
- Cooke, R. S. et al. 2026. Mapping of C5-blocking monoclonal antibodies reveals new C5 inhibitory epitopes and novel modes of C5 inhibition. Immunology (10.1111/imm.70180)
- Keat, S. B. K. et al. 2026. Activation of the lectin pathway drives persistent complement dysregulation in long COVID. Immunology 178 (2), pp.261-268. (10.1111/imm.70110)
- Mannes, M. , Zelek, W. M. and Trouw, L. A. 2026. Shifting from systemic to precision‐targeted complement therapies: opportunities and hurdles. European Journal of Immunology 56 (6) e70231. (10.1002/eji.70231)
- Dodd, K. C. et al., 2026. Lymphocyte alterations and elevated complement signaling are key features of refractory myasthenia gravis. Med 7 (3) 100987. (10.1016/j.medj.2025.100987)
- Daskoulidou, N. et al., 2026. Complement in brain and eye disease: shared mechanisms, convergent pathologies, and common therapeutic opportunities. Mammalian Genome 37 (1) 33. (10.1007/s00335-026-10199-3)
2025
- Bright, M. T. et al. 2025. Complement gene expression profiles are altered in the AD frontal cortex [Abstract]. Alzheimer's & Dementia: The Journal of the Alzheimer's Association 21 e100157. (10.1002/alz70855_100157)
- Nguyen, V. D. et al. 2025. Complement biosynthesis in human brain: Insights from single-nucleus transcriptomics of hippocampus.. BioRxiv (10.1101/2025.05.06.652374)
- Byrne, R. A. et al. 2025. The schizophrenia-associated gene CSMD1 encodes a complement classical pathway inhibitor predominantly expressed by astrocytes and at synapses in mice and humans. Brain, Behavior, and Immunity 127 , pp.287-302. (10.1016/j.bbi.2025.03.026)
- Zelek, W. M. and Tenner, A. J. 2025. Complement therapeutics in neurodegenerative diseases. Immunobiology 230 (4) 153089. (10.1016/j.imbio.2025.153089)
- Li, Y. et al., 2025. Enhanced immunocompatibility and hemocompatibility of nanomedicines across multiple species using complement pathway inhibitors. Science Advances 11 (28) eadw1731. (10.1126/sciadv.adw1731)
- Daskoulidou, N. et al. 2025. The Alzheimer's disease‐associated complement receptor 1 variant confers risk by impacting glial phagocytosis. Alzheimer's & Dementia: The Journal of the Alzheimer's Association 21 (7) e70458. (10.1002/alz.70458)
- Cooke, R. S. et al. 2025. CD59, disulphide‐locked human C9 and horse C9 inhibit human membrane attack complex assembly by similar mechanisms. Immunology (10.1111/imm.70008)
- Chen, D. et al., 2025. Inhibition of terminal complement complex formation alleviates murine antibody-mediated TRALI. Blood 146 (6), pp.759-764. (10.1182/blood.2024028012)
- Reed, R. M. et al., 2025. Plasma complement system markers and their association with cardiometabolic risk factors: an ethnic comparison of White European and Black African men. Endocrinology and Metabolism 328 (4), pp.e611-e619. (10.1152/ajpendo.00419.2024)
- Smith-Jackson, K. et al., 2025. The membrane attack complex drives thrombotic microangiopathy in complement mediated atypical hemolytic uremic syndrome. Kidney International 107 (4), pp.700-713. (10.1016/j.kint.2024.12.016)
- Zelek, W. M. et al. 2025. Brain-penetrant complement inhibition mitigates neurodegeneration in an Alzheimer's disease mouse model. Brain 148 (3), pp.941-954. (10.1093/brain/awae278)
- Zelek, W. M. et al. 2025. Targeting novel anti‐complement drugs to the brain reduces complement activation and synapse loss, and improves cognition in a mouse model of dementia. Alzheimer's & Dementia: The Journal of the Alzheimer's Association 20 (S6)(10.1002/alz.090708)
2024
- Kharnaf, M. et al., 2024. Factor XII promotes the thromboinflammatory response in a rat model of veno-arterial extracorporeal membrane oxygenation.. The Journal of Thoracic and Cardiovascular Surgery 168 (2), pp.E37-E53. (10.1016/j.jtcvs.2023.08.045)
- Zelek, W. M. 2024. Is Long COVID a complement dysregulation disease?. Clinical Chemistry (10.1093/clinchem/hvae088)
- Zelek, W. M. , Bevan, R. J. and Morgan, B. P. 2024. Targeting terminal pathway reduces brain complement activation, amyloid load and synapse loss, and improves cognition in a mouse model of dementia. Brain, Behavior, and Immunity 118 , pp.355-363. (10.1016/j.bbi.2024.03.017)
- Nimmo, J. et al. 2024. The complement system in neurodegenerative diseases. Clinical Science 138 (6), pp.387-412. (10.1042/cs20230513)
- Baillie, K. et al. 2024. Complement dysregulation is a prevalent and therapeutically amenable feature of long COVID. Med 5 (3), pp.239-253. (10.1016/j.medj.2024.01.011)
- Kodosaki, E. et al. 2024. Combination protein biomarkers predict multiple sclerosis diagnosis and outcomes. Journal of Neuroinflammation 21 (1) 52. (10.1186/s12974-024-03036-4)
- Daskoulidou, N. et al. 2024. Involvement of complement in Alzheimer's Disease: From genetics through pathology to therapeutic strategies. In: Ellenbroek, B. A. et al., Current Topics in Behavioral Neurosciences. Springer, Berlin, Heidelberg. , pp.1-22. (10.1007/7854_2024_524)
2023
- Kamegai, N. et al., 2023. Complement terminal pathway inhibition reduces peritoneal injuries in a rat peritonitis model. Clinical & Experimental Immunology 214 (2), pp.209-218. (10.1093/cei/uxad088)
- Veteleanu, A. et al., 2023. Alzheimer’s disease-associated complement gene variants influence plasma complement protein levels. Journal of Neuroinflammation 20 (1) 169. (10.1186/s12974-023-02850-6)
- Zelek, W. M. and Harrison, R. A. 2023. Complement and COVID-19: Three years on, what we know, what we don't know, and what we ought to know. Immunobiology 228 (3) 152393. (10.1016/j.imbio.2023.152393)
- Veteleanu, A. et al. 2023. Complement dysregulation and Alzheimer's disease in Down syndrome. Alzheimer's & Dementia: The Journal of the Alzheimer's Association 19 (4), pp.1383-1392. (10.1002/alz.12799)
- Goff, L. M. et al., 2023. Ethnic differences in complement system biomarkers and their association with metabolic health in men of Black African and White European ethnicity. Clinical & Experimental Immunology 212 (1)(10.1093/cei/uxad011)
- Siggins, M. K. et al., 2023. Alternative pathway dysregulation in tissues drives sustained complement activation and predicts outcome across the disease course in COVID-19.. Immunology 168 (3), pp.473-492. (10.1111/imm.13585)
2022
- Lekova, E. et al., 2022. Discovery of functionally distinct anti-C7 monoclonal antibodies and stratification of anti-nicotinic AChR positive Myasthenia Gravis patients. Frontiers in Immunology 13 968206. (10.3389/fimmu.2022.968206)
- Zelek, W. M. and Morgan, B. P. 2022. Targeting complement in neurodegeneration: challenges, risks, and strategies. Trends in Pharmacological Sciences 43 (8), pp.615-628. (10.1016/j.tips.2022.02.006)
- Carpanini, S. M. et al. 2022. Terminal complement pathway activation drives synaptic Loss in Alzheimer’s disease models. Acta Neuropathologica Communications 10 99. (10.1186/s40478-022-01404-w)
- Fielding, C. A. et al. 2022. SARS-CoV-2 host-shutoff impacts innate NK cell functions, but antibody-dependent NK activity is strongly activated through non-spike antibodies. eLife 11 (10.7554/eLife.74489)
- Lewis, L. A. et al., 2022. Efficacy of an experimental gonococcal lipooligosaccharide mimitope vaccine requires terminal complement. The Journal of Infectious Diseases 225 (10), pp.1861–1864. (10.1093/infdis/jiab630)
- Kolka, C. M. et al., 2022. C5b-9 membrane attack complex formation and extracellular vesicle shedding in Barrett's esophagus and esophageal adenocarcinoma. Frontiers in Immunology 13 842023. (10.3389/fimmu.2022.842023)
- Scurr, M. et al. 2022. Whole blood-based measurement of SARS-CoV-2-specific T cells reveals asymptomatic infection and vaccine immunogenicity in healthy subjects and patients with solid organ cancers. Immunology 165 (2), pp.250-259. (10.1111/imm.13433)
2021
- Syrimi, E. et al., 2021. The immune landscape of SARS-CoV-2-associated multisystem inflammatory syndrome in children (MIS-C) from acute disease to recovery. iScience 24 (11) 103215. (10.1016/j.isci.2021.103215)
- Zelek, W. 2021. Measuring total classical pathway and activities of individual components of the mouse complement pathway. Bio-protocol 11 (19) e4175. (10.21769/BioProtoc.4175)
- Mc Mahon, O. et al., 2021. The rare C9 P167S risk variant for age-related macular degeneration increases polymerization of the terminal component of the complement cascade. Human Molecular Genetics 30 (13), pp.1188-1199. (10.1093/hmg/ddab086)
- Webster, J. A. et al., 2021. Development of EndoScreen chip, a microfluidic pre-endoscopy triage test for esophageal adenocarcinoma. Cancers 13 (12) 2865. (10.3390/cancers13122865)
- Moat, S. J. et al. 2021. Development of a high throughput SARS-CoV-2 antibody testing pathway using dried blood spot specimens. Annals of Clinical Biochemistry 58 (2)(10.1177/0004563220981106)
- Murrell, I. et al. 2021. Temporal development and neutralising potential of antibodies against SARS-CoV-2 in hospitalised COVID-19 patients: An observational cohort study. PLoS ONE 16 (1) e0245382. (10.1371/journal.pone.0245382)
2020
- Buckland, M. S. et al., 2020. Treatment of COVID-19 with remdesivir in the absence of humoral immunity: a case report. Nature Communications 11 (1) 6385. (10.1038/s41467-020-19761-2)
- Zelek, W. M. and Morgan, B. P. 2020. Monoclonal antibodies capable of inhibiting complement downstream of C5 in multiple species. Frontiers in Immunology 11 (11) 612402. (10.3389/fimmu.2020.612402)
- Zelek, W. M. et al. 2020. Cerebrospinal fluid complement system biomarkers in demyelinating disease. Multiple Sclerosis 26 (14), pp.1929-1937. (10.1177/1352458519887905)
- Zelek, W. M. et al. 2020. Complement inhibition with the C5 blocker LFG316 in severe COVID-19. American Journal of Respiratory and Critical Care Medicine 202 (9), pp.1304-1308. (10.1164/rccm.202007-2778LE)
- Zelek, W. M. et al. 2020. Characterising the original anti-C5 function-blocking antibody, BB5.1, for species specificity, mode of action and interactions with C5. Immunology 161 (2), pp.103-113. Volume161, Issue2 October 2020 Pages 103-113. (10.1111/imm.13228)
2019
- Zelek, W. 2019. Targeting the terminal pathway in complement – driven disease.. PhD Thesis , Cardiff University.
- Zelek, W. M. et al. 2019. Compendium of current complement therapeutics. Molecular Immunology 114 , pp.341-352. (10.1016/j.molimm.2019.07.030)
- Zelek, W. M. , Taylor, P. R. and Morgan, B. P. 2019. Development and characterisation of novel anti-C5 monoclonal antibodies capable of inhibiting complement in multiple species. Immunology 157 (4), pp.283-295. (10.1111/imm.13083)
- Zelek, W. M. et al. 2019. Measurement of soluble CD59 in CSF in demyelinating disease: Evidence for an intrathecal source of soluble CD59. Multiple Sclerosis 25 (4), pp.523-531. (10.1177/1352458518758927)
- Kopczynska, M. et al. 2019. Complement system biomarkers in first episode psychosis. Schizophrenia Research 204 , pp.16-22. (10.1016/j.schres.2017.12.012)
2018
- Zelek, W. M. , Harris, C. L. and Morgan, B. P. 2018. Extracting the barbs from complement assays: Identification and optimisation of a safe substitute for traditional buffers. Immunobiology 223 (12), pp.744-749. (10.1016/j.imbio.2018.07.016)
- Zelek, W. M. et al. 2018. Characterising a pH-switch anti-C5 antibody as a tool for human and mouse complement C5 purification and cross-species inhibition of classical and reactive lysis. Immunology 155 (3), pp.396-403. (10.1111/imm.12982)
- Kopczynska, M. et al. 2018. Complement system biomarkers in epilepsy. Seizure - European Journal of Epilepsy 60 , pp.1-7. (10.1016/j.seizure.2018.05.016)
- Boshra, H. et al., 2018. Absence of CD59 in guinea pigs: Analysis of the Cavia porcellus genome suggests the evolution of a CD59 pseudogene. Journal of Immunology 200 (1), pp.327-335. (10.4049/jimmunol.1701238)
Adrannau llyfrau
- Daskoulidou, N. et al. 2024. Involvement of complement in Alzheimer's Disease: From genetics through pathology to therapeutic strategies. In: Ellenbroek, B. A. et al., Current Topics in Behavioral Neurosciences. Springer, Berlin, Heidelberg. , pp.1-22. (10.1007/7854_2024_524)
Erthyglau
- Arun, T. et al., 2026. Non-invasive biomarkers for neurosarcoidosis: Complement activation as a tool for diagnosis and prognosis. Journal of Neuroimmunology 418 578969. (10.1016/j.jneuroim.2026.578969)
- Cooke, R. S. et al. 2026. Mapping of C5-blocking monoclonal antibodies reveals new C5 inhibitory epitopes and novel modes of C5 inhibition. Immunology (10.1111/imm.70180)
- Keat, S. B. K. et al. 2026. Activation of the lectin pathway drives persistent complement dysregulation in long COVID. Immunology 178 (2), pp.261-268. (10.1111/imm.70110)
- Mannes, M. , Zelek, W. M. and Trouw, L. A. 2026. Shifting from systemic to precision‐targeted complement therapies: opportunities and hurdles. European Journal of Immunology 56 (6) e70231. (10.1002/eji.70231)
- Dodd, K. C. et al., 2026. Lymphocyte alterations and elevated complement signaling are key features of refractory myasthenia gravis. Med 7 (3) 100987. (10.1016/j.medj.2025.100987)
- Daskoulidou, N. et al., 2026. Complement in brain and eye disease: shared mechanisms, convergent pathologies, and common therapeutic opportunities. Mammalian Genome 37 (1) 33. (10.1007/s00335-026-10199-3)
- Bright, M. T. et al. 2025. Complement gene expression profiles are altered in the AD frontal cortex [Abstract]. Alzheimer's & Dementia: The Journal of the Alzheimer's Association 21 e100157. (10.1002/alz70855_100157)
- Nguyen, V. D. et al. 2025. Complement biosynthesis in human brain: Insights from single-nucleus transcriptomics of hippocampus.. BioRxiv (10.1101/2025.05.06.652374)
- Byrne, R. A. et al. 2025. The schizophrenia-associated gene CSMD1 encodes a complement classical pathway inhibitor predominantly expressed by astrocytes and at synapses in mice and humans. Brain, Behavior, and Immunity 127 , pp.287-302. (10.1016/j.bbi.2025.03.026)
- Zelek, W. M. and Tenner, A. J. 2025. Complement therapeutics in neurodegenerative diseases. Immunobiology 230 (4) 153089. (10.1016/j.imbio.2025.153089)
- Li, Y. et al., 2025. Enhanced immunocompatibility and hemocompatibility of nanomedicines across multiple species using complement pathway inhibitors. Science Advances 11 (28) eadw1731. (10.1126/sciadv.adw1731)
- Daskoulidou, N. et al. 2025. The Alzheimer's disease‐associated complement receptor 1 variant confers risk by impacting glial phagocytosis. Alzheimer's & Dementia: The Journal of the Alzheimer's Association 21 (7) e70458. (10.1002/alz.70458)
- Cooke, R. S. et al. 2025. CD59, disulphide‐locked human C9 and horse C9 inhibit human membrane attack complex assembly by similar mechanisms. Immunology (10.1111/imm.70008)
- Chen, D. et al., 2025. Inhibition of terminal complement complex formation alleviates murine antibody-mediated TRALI. Blood 146 (6), pp.759-764. (10.1182/blood.2024028012)
- Reed, R. M. et al., 2025. Plasma complement system markers and their association with cardiometabolic risk factors: an ethnic comparison of White European and Black African men. Endocrinology and Metabolism 328 (4), pp.e611-e619. (10.1152/ajpendo.00419.2024)
- Smith-Jackson, K. et al., 2025. The membrane attack complex drives thrombotic microangiopathy in complement mediated atypical hemolytic uremic syndrome. Kidney International 107 (4), pp.700-713. (10.1016/j.kint.2024.12.016)
- Zelek, W. M. et al. 2025. Brain-penetrant complement inhibition mitigates neurodegeneration in an Alzheimer's disease mouse model. Brain 148 (3), pp.941-954. (10.1093/brain/awae278)
- Zelek, W. M. et al. 2025. Targeting novel anti‐complement drugs to the brain reduces complement activation and synapse loss, and improves cognition in a mouse model of dementia. Alzheimer's & Dementia: The Journal of the Alzheimer's Association 20 (S6)(10.1002/alz.090708)
- Kharnaf, M. et al., 2024. Factor XII promotes the thromboinflammatory response in a rat model of veno-arterial extracorporeal membrane oxygenation.. The Journal of Thoracic and Cardiovascular Surgery 168 (2), pp.E37-E53. (10.1016/j.jtcvs.2023.08.045)
- Zelek, W. M. 2024. Is Long COVID a complement dysregulation disease?. Clinical Chemistry (10.1093/clinchem/hvae088)
- Zelek, W. M. , Bevan, R. J. and Morgan, B. P. 2024. Targeting terminal pathway reduces brain complement activation, amyloid load and synapse loss, and improves cognition in a mouse model of dementia. Brain, Behavior, and Immunity 118 , pp.355-363. (10.1016/j.bbi.2024.03.017)
- Nimmo, J. et al. 2024. The complement system in neurodegenerative diseases. Clinical Science 138 (6), pp.387-412. (10.1042/cs20230513)
- Baillie, K. et al. 2024. Complement dysregulation is a prevalent and therapeutically amenable feature of long COVID. Med 5 (3), pp.239-253. (10.1016/j.medj.2024.01.011)
- Kodosaki, E. et al. 2024. Combination protein biomarkers predict multiple sclerosis diagnosis and outcomes. Journal of Neuroinflammation 21 (1) 52. (10.1186/s12974-024-03036-4)
- Kamegai, N. et al., 2023. Complement terminal pathway inhibition reduces peritoneal injuries in a rat peritonitis model. Clinical & Experimental Immunology 214 (2), pp.209-218. (10.1093/cei/uxad088)
- Veteleanu, A. et al., 2023. Alzheimer’s disease-associated complement gene variants influence plasma complement protein levels. Journal of Neuroinflammation 20 (1) 169. (10.1186/s12974-023-02850-6)
- Zelek, W. M. and Harrison, R. A. 2023. Complement and COVID-19: Three years on, what we know, what we don't know, and what we ought to know. Immunobiology 228 (3) 152393. (10.1016/j.imbio.2023.152393)
- Veteleanu, A. et al. 2023. Complement dysregulation and Alzheimer's disease in Down syndrome. Alzheimer's & Dementia: The Journal of the Alzheimer's Association 19 (4), pp.1383-1392. (10.1002/alz.12799)
- Goff, L. M. et al., 2023. Ethnic differences in complement system biomarkers and their association with metabolic health in men of Black African and White European ethnicity. Clinical & Experimental Immunology 212 (1)(10.1093/cei/uxad011)
- Siggins, M. K. et al., 2023. Alternative pathway dysregulation in tissues drives sustained complement activation and predicts outcome across the disease course in COVID-19.. Immunology 168 (3), pp.473-492. (10.1111/imm.13585)
- Lekova, E. et al., 2022. Discovery of functionally distinct anti-C7 monoclonal antibodies and stratification of anti-nicotinic AChR positive Myasthenia Gravis patients. Frontiers in Immunology 13 968206. (10.3389/fimmu.2022.968206)
- Zelek, W. M. and Morgan, B. P. 2022. Targeting complement in neurodegeneration: challenges, risks, and strategies. Trends in Pharmacological Sciences 43 (8), pp.615-628. (10.1016/j.tips.2022.02.006)
- Carpanini, S. M. et al. 2022. Terminal complement pathway activation drives synaptic Loss in Alzheimer’s disease models. Acta Neuropathologica Communications 10 99. (10.1186/s40478-022-01404-w)
- Fielding, C. A. et al. 2022. SARS-CoV-2 host-shutoff impacts innate NK cell functions, but antibody-dependent NK activity is strongly activated through non-spike antibodies. eLife 11 (10.7554/eLife.74489)
- Lewis, L. A. et al., 2022. Efficacy of an experimental gonococcal lipooligosaccharide mimitope vaccine requires terminal complement. The Journal of Infectious Diseases 225 (10), pp.1861–1864. (10.1093/infdis/jiab630)
- Kolka, C. M. et al., 2022. C5b-9 membrane attack complex formation and extracellular vesicle shedding in Barrett's esophagus and esophageal adenocarcinoma. Frontiers in Immunology 13 842023. (10.3389/fimmu.2022.842023)
- Scurr, M. et al. 2022. Whole blood-based measurement of SARS-CoV-2-specific T cells reveals asymptomatic infection and vaccine immunogenicity in healthy subjects and patients with solid organ cancers. Immunology 165 (2), pp.250-259. (10.1111/imm.13433)
- Syrimi, E. et al., 2021. The immune landscape of SARS-CoV-2-associated multisystem inflammatory syndrome in children (MIS-C) from acute disease to recovery. iScience 24 (11) 103215. (10.1016/j.isci.2021.103215)
- Zelek, W. 2021. Measuring total classical pathway and activities of individual components of the mouse complement pathway. Bio-protocol 11 (19) e4175. (10.21769/BioProtoc.4175)
- Mc Mahon, O. et al., 2021. The rare C9 P167S risk variant for age-related macular degeneration increases polymerization of the terminal component of the complement cascade. Human Molecular Genetics 30 (13), pp.1188-1199. (10.1093/hmg/ddab086)
- Webster, J. A. et al., 2021. Development of EndoScreen chip, a microfluidic pre-endoscopy triage test for esophageal adenocarcinoma. Cancers 13 (12) 2865. (10.3390/cancers13122865)
- Moat, S. J. et al. 2021. Development of a high throughput SARS-CoV-2 antibody testing pathway using dried blood spot specimens. Annals of Clinical Biochemistry 58 (2)(10.1177/0004563220981106)
- Murrell, I. et al. 2021. Temporal development and neutralising potential of antibodies against SARS-CoV-2 in hospitalised COVID-19 patients: An observational cohort study. PLoS ONE 16 (1) e0245382. (10.1371/journal.pone.0245382)
- Buckland, M. S. et al., 2020. Treatment of COVID-19 with remdesivir in the absence of humoral immunity: a case report. Nature Communications 11 (1) 6385. (10.1038/s41467-020-19761-2)
- Zelek, W. M. and Morgan, B. P. 2020. Monoclonal antibodies capable of inhibiting complement downstream of C5 in multiple species. Frontiers in Immunology 11 (11) 612402. (10.3389/fimmu.2020.612402)
- Zelek, W. M. et al. 2020. Cerebrospinal fluid complement system biomarkers in demyelinating disease. Multiple Sclerosis 26 (14), pp.1929-1937. (10.1177/1352458519887905)
- Zelek, W. M. et al. 2020. Complement inhibition with the C5 blocker LFG316 in severe COVID-19. American Journal of Respiratory and Critical Care Medicine 202 (9), pp.1304-1308. (10.1164/rccm.202007-2778LE)
- Zelek, W. M. et al. 2020. Characterising the original anti-C5 function-blocking antibody, BB5.1, for species specificity, mode of action and interactions with C5. Immunology 161 (2), pp.103-113. Volume161, Issue2 October 2020 Pages 103-113. (10.1111/imm.13228)
- Zelek, W. M. et al. 2019. Compendium of current complement therapeutics. Molecular Immunology 114 , pp.341-352. (10.1016/j.molimm.2019.07.030)
- Zelek, W. M. , Taylor, P. R. and Morgan, B. P. 2019. Development and characterisation of novel anti-C5 monoclonal antibodies capable of inhibiting complement in multiple species. Immunology 157 (4), pp.283-295. (10.1111/imm.13083)
- Zelek, W. M. et al. 2019. Measurement of soluble CD59 in CSF in demyelinating disease: Evidence for an intrathecal source of soluble CD59. Multiple Sclerosis 25 (4), pp.523-531. (10.1177/1352458518758927)
- Kopczynska, M. et al. 2019. Complement system biomarkers in first episode psychosis. Schizophrenia Research 204 , pp.16-22. (10.1016/j.schres.2017.12.012)
- Zelek, W. M. , Harris, C. L. and Morgan, B. P. 2018. Extracting the barbs from complement assays: Identification and optimisation of a safe substitute for traditional buffers. Immunobiology 223 (12), pp.744-749. (10.1016/j.imbio.2018.07.016)
- Zelek, W. M. et al. 2018. Characterising a pH-switch anti-C5 antibody as a tool for human and mouse complement C5 purification and cross-species inhibition of classical and reactive lysis. Immunology 155 (3), pp.396-403. (10.1111/imm.12982)
- Kopczynska, M. et al. 2018. Complement system biomarkers in epilepsy. Seizure - European Journal of Epilepsy 60 , pp.1-7. (10.1016/j.seizure.2018.05.016)
- Boshra, H. et al., 2018. Absence of CD59 in guinea pigs: Analysis of the Cavia porcellus genome suggests the evolution of a CD59 pseudogene. Journal of Immunology 200 (1), pp.327-335. (10.4049/jimmunol.1701238)
Gosodiad
- Zelek, W. 2019. Targeting the terminal pathway in complement – driven disease.. PhD Thesis , Cardiff University.
Ymchwil
Rwy'n datblygu therapiwteg cyflenwad ymennydd i drin clefydau niwroddirywiol.
Bywgraffiad
Arweinydd Grŵp, Sefydliad Ymchwil Dementia y DU ym Mhrifysgol Caerdydd
Cymrawd Arweinwyr y Dyfodol UKRI, Ras yn Erbyn Dementia / Cymrawd ARUK
Arwain ymchwil drosiadol ar therapiwteg cyflenwad ar gyfer niwroddirywiad, gan gynnwys gwrthgyrff ymennydd a moleciwlau bach.
Meysydd goruchwyliaeth
Goruchwyliaeth gyfredol
Rebekah Cooke
News articles
Contact Details
[email protected]
+44 29206 87860
Adeilad Henry Wellcome ar gyfer Ymchwil Biofeddygol, Llawr 4ydd Llawr, Ystafell 4F10, Ysbyty Athrofaol Cymru, Parc y Mynydd Bychan, Caerdydd, CF14 4XN
+44 29206 87860
Adeilad Henry Wellcome ar gyfer Ymchwil Biofeddygol, Llawr 4ydd Llawr, Ystafell 4F10, Ysbyty Athrofaol Cymru, Parc y Mynydd Bychan, Caerdydd, CF14 4XN
